Clinical Data Parsortix study shows promise for ADC target detection PharmaTimesResearchers highlight minimally invasive monitoring potentialOncologyRead full story pharminent August 3, 2026 (Last updated: August 3, 2026) PharmaTimes Researchers highlight minimally invasive monitoring potential Oncology Read full story Post navigation Previous: Novo Nordisk’s Ziltivekimab Misses Primary Endpoint in Pivotal Cardiovascular TrialNext: Curium strikes $8bn deal to buy radiopharma rival Lantheus Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026